Showing 3771-3780 of 5268 results for "".
- Can Harnessing a Tumor’s Power Help Heal Diabetic Foot Ulcers?https://practicaldermatology.com/news/can-harnessing-a-tumors-power-help-heal-diabetic-foot-ulcers/2461480/Scientists may have found a way to train healthy immune cells to accelerate diabetic wound healing. The findings appear in EMBO Molecular Medicine. Diabetic foot ulcers result in
- Apyx Medical Launches #ThisIsMe Campaign for Renuvionhttps://practicaldermatology.com/news/apyx-medical-launches-thisisme-campaign-for-renuvion/2461478/Apyx Medical Corporation is rolling out its first-ever direct-to-consumer brand campaign for Renuvion, a proprietary helium plasma and radiofrequency technology. The #ThisIsMe campaign is aimed at U.S. consumers who are interested in a minimally invas
- Hyphens Pharma Licenses Winlevi for 10 ASEAN Countries from Cosmo Pharmaceuticalshttps://practicaldermatology.com/news/hyphens-pharma-licenses-winlevi-for-10-asean-countries-from-cosmo-pharmaceuticals/2461475/Hyphens Pharma International Limited’s subsidiary Hyphens Pharma Pte. Ltd. has entered into exclusive license and supply agreements with Cassiopea S.p.A to develop and commercialize Winlevi (clascoterone) cream 1% and all future product extensions and/or improvemenst in the treat
- Soligenix Initiates Phase 2 Trial of SGX302 for Mild to Moderate Psoriasishttps://practicaldermatology.com/news/soligenix-initiates-phase-2-trial-of-sgx302-for-mild-to-moderate-psoriasis/2461471/Patient enrollment has been opened for Soligenix, Inc.'s Phase 2a study evaluating SGX302 (synthetic hypericin) for the treatment of mild to moderate psoriasis. "We are excited to expand synthetic hypericin's development into different cutaneous T-cell diseases such as psor
- Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancerhttps://practicaldermatology.com/news/immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer/2461468/Vaccine exclusively delivered with the PharmaJet Stratis® Needle-free Injection System
- Promising and Consistent Topline Results Seen in Phase 3 Trial of Roflumilast in ADhttps://practicaldermatology.com/news/promising-and-consistent-topline-results-seen-in-phase-3-trial-of-roflumilast-in-ad/2461466/Arcutis Biotherapeutics, Inc.’s roflumilast met the key primary and secondary endpoints in the INT
- Zubin Meshginpoosh Named President and COO at Sentéhttps://practicaldermatology.com/news/zubin-meshginpoosh-named-president-and-coo-at-sente/2461463/Zubin Meshginpoosh is now the President and Chief Operational Officer of Senté. "Zubin has an incredible track record for enabling teams to achieve success in high growth and fast-changing environments," says Faheem Hasnain, Chairman of the Board at Senté, in a n
- UCB’s Bimekizumab Performs Well in PsA Studieshttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-psa-studies/2461460/Two new studies highlight the efficacy and safety of bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and/or tumor necrosis factor inhibitor inadequate responders (TNFi-IR). The 24-week results from the Phase 3 BE OPTIMAL study and 16-w
- NEA Announces 2022 Research Grant Recipientshttps://practicaldermatology.com/news/nea-announces-2022-research-grant-recipients/2461457/The National Eczema Association (NEA) announced the recipients for its 2022 research grants. Fro
- Study: Isolated Nail PsO Not Linked to Metabolic Syndrome Riskhttps://practicaldermatology.com/news/study-isolated-nail-psoriasis-not-linked-to-metabolic-syndrome-risk/2461456/Isolated nail psoriasis does not increase risk for metabolic syndrome, according to a letter to the editor in the Journal of the European Academy of Dermatology & Venereology. The analysis include